Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: The anti-inflammatory Annexin A1 induces the clearance and degradation of the amyloid-β peptide

Fig. 2

Treatment of neuroblastoma cells with recombinant ANXA1 reduces the levels of soluble Aβ. a Representative Western blots and quantification of soluble Aβ in the medium of N2asw cells treated with 0.5–4 μg/ml hrANXA1 for 18 h (n = 9–24 samples) or transfected with control or ANXA1 siRNA (n = 15 samples). b Representative Western blots and quantification of full-length APP protein expression in N2asw cells treated with 1–4 μg/ml hrANXA1 for 18 h (n = 3–11 samples) or transfected with control or ANXA1 siRNA (n = 15 samples) and normalised to β-actin. c Representative Western blots and quantification of soluble APPα in the medium of N2asw cells treated with 1–4 μg/ml hrANXA1 for 18 h (n = 3–11 samples). Values shown in graphs represent the mean value ± SEM and are expressed as fold change in comparison to the normalized control. Statistical analysis included one-way ANOVA with Bonferroni’s multiple-comparison post-test or independent two-tailed Student’s t test, *p < 0.05, **p < 0.01, ****p < 0.0001

Back to article page